Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection

J Infect Dis. 2011 Sep 1;204(5):777-82. doi: 10.1093/infdis/jir397.

Abstract

A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.

MeSH terms

  • Adolescent
  • Adult
  • Child, Preschool
  • Critical Illness
  • Drug Therapy, Combination
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype*
  • Influenza, Human / drug therapy*
  • Infusions, Intravenous
  • Middle Aged
  • Netherlands
  • Oseltamivir / therapeutic use
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Zanamivir / administration & dosage
  • Zanamivir / therapeutic use*

Substances

  • Oseltamivir
  • Zanamivir